MDCX vs MENS

Medicus Pharma Ltd. vs Jyong Biotech Ltd. — Valuation Comparison 2026

MDCX

Pharmaceutical Preparations
Medicus Pharma Ltd.
Quality
3.2
out of 10
Value Trap
12
SAFE
Price
$0.38
Last close
Models
7/13
Active
VS

MENS

Pharmaceutical Preparations
Jyong Biotech Ltd.
Quality
2.3
out of 10
Value Trap
Price
$2.20
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType MDCX Fair ValueMDCX Upside MENS Fair ValueMENS Upside
Bayesian DCF Intrinsic $0.11 -69.8% $0.56 -74.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.21 -43.4% $1.44 -34.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $0.17 -92.1%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for MDCX vs MENS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MDCX vs MENS — Which Stock Is More Undervalued?

MDCX scores higher with a 3.2/10 quality rating vs MENS's 2.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Medicus Pharma Ltd. (MDCX) and Jyong Biotech Ltd. (MENS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MDCX currently trades at $0.38 with a QOC of 3.2/10, while MENS trades at $2.20 with a QOC of 2.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).